FDA Accepts Application for Genentech ’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition

South San Francisco, CA -- September 4, 2023 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news